Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.
1. A cell-binding agent-drug conjugate compound of Formula (VIII):
wherein Formula (VIII) is Formula (VIII′):
wherein:
n is 1-20; and
T is N—C(O)—CH 2 —N—N or N—C(O)—CH 2 CH 2 —N—N,
Cb represents a cell-binding agent of an antibody or a functional fragment thereof;
Drug, Drug′, and Drug″ represent same or different of, a cytotoxic agent, or a therapeutic drug, an antibody or an antibody fragment, or siRNA, miRNA, mRNA, piRNA, or DNA, which is linked to the cell-binding agent via the linker through R 1 , R 1 ′, and R 1 ″ respectively containing a C 1 -C 8 alkane; C 2 -C 8 alkylene, alkenylene, alkynylene, aromatic, ether, polyoxyalkylene, ester, amine, imine, polyamine, hydrazine, hydrazone, amide, urea, semicarbazide, carbazide, alkoxyamine, urethanes, amino acid, peptide, acyloxylamine, hydroxamic acid, disulfide, thioether, thioester, carbamate, carbonate, heterocyclic ring, heteroalkyl, heteroaromatic, or alkoxime; or a combination thereof, wherein at least one of Drug, Drug′ and Drug″ is a tubulysin molecule;
“ ” represents either single bond or double bond;
m 1 , m 1′ , and m 1″ are independently an integer from 1 to 10;
m 2 , m 2′ , m 2″ and m 4 are 1;
R 1 , R 1′ , and R 1″ , are same or different, and are C 1 -C 8 alkyl; C 2 -C 8 heteroalkyl, alkylcycloalkyl, or heterocycloalkyl; C 3 -C 8 aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; or C 2 -C 8 ester, ether, or amide; or polyethyleneoxy unit of formula (OCH 2 CH 2 ) p or (OCH 2 CH(CH 3 )) p , wherein p is an integer from 0 to about 1000, or a combination thereof,
X 1 , X 1′ , L 2 , L 2′ and L 2′″ are absent;
L 1 , L 1′ , and L 1″ are same or different and independently O, NH, S, NHNH, N(R 3 ), N(R 3 )N(R 3′ ), polyethyleneoxy unit of formula (OCH 2 CH 2 ) p OR 3 , or (OCH 2 CH(CH 3 )) p OR 3 , or NH(CH 2 CH 2 O) p R 3 , or NH(CH 2 CH(CH 3 )O) p R 3 , or N[(CH 2 CH 2 O) p R 3 ][(CH 2 CH 2 O) p′ R 3′ ], or (OCH 2 CH 2 ) p C(═O)X 1 R 3 , or CH 2 CH 2 (OCH 2 CH 2 ) p C(═O)X 1 R 3 , wherein p and p′ are independently an integer selected from 1 to about 1000, or a combination thereof; C 1 -C 8 alkyl; C 2 -C 8 heteroalkyl, alkylcycloalkyl, or heterocycloalkyl; C 3 -C 8 aryl, Ar-alkyl, heterocyclic, carbocyclic, cycloalkyl, heteroalkylcycloalkyl, alkylcarbonyl, or heteroaryl; wherein X 1 , R 3 and R 3 ′ are defined above;
or L 1 , L 1′ , or L 1″ contains a group of self-immolative or a non-self-immolative component, peptidic units (1-8 of natural or unnatural amino acids), a hydrazone bond, a disulfide, an ester, an oxime, an amide, or a thioether bond;
the self-immolative unit comprises an aromatic compound selected from the group consisting of para-aminobenzylcarbamoyl (PAB) groups, 2-aminoimidazol-5-methanol compounds, heterocyclic PAB compounds, beta-glucuronide, and ortho or para-aminobenzylacetals; the self-immolative unit has one of following structures:
wherein the (*) atom is the point of attachment of additional spacer or releasable linker units, or a cytotoxic agent, and/or a binding molecule (CBA); X 1 , Y 1 , Z 2 and Z 3 are independently NH, O, or S; Z 1 is independently H, NHR 1 , OR 1 , SR 1 , COX 1 R 1 , wherein X 1 and R 1 are defined above; v is 0 or 1; U 1 is independently H, OH, C 1 -C 6 alkyl, (OCH 2 CH 2 ) n , F, Cl, Br, I, OR 5 , SR 5 , NR 5 R 5 ′, N═NR 5 , N═R 5 , NR 5 R 5 ′, NO 2 , SOR 5 R 5 ′, SO 2 R 5 , SO 3 R 5 , OSO 3 R 5 , PR 5 R 5 ′, POR 5 R 5 ′, PO 2 R 5 R 5 ′, OPO(OR 5 )(OR 5 ′), or OCH 2 PO(OR 5 (OR 5 ′), wherein R 5 and R 5 ′ are independently H, C 1 ˜C 8 alkyl; C 2 ˜C 8 alkenyl, alkynyl, heteroalkyl, or aminocaine; C 3 ˜C 8 aryl, heterocyclic, carbocyclic, cycloalkyl, heterocycloalkyl, heteroaralkyl, alkylcarbonyl, or glycoside; or pharmaceutical cation salts;
the non-self-immolative linker component is one of following structures:
wherein the (*) atom is a point of attachment of additional spacer or releasable linker, a cytotoxic agent, and/or a binding molecule; X 1 , Y 1 , U 1 , R 5 , R 5 ′ are defined as above; r is 0-100; m and n are 0˜6 independently;
or L 1 , L 1′ , L 1″ and L 1′″ are independently absent;
or L 1 , L 1′ , L 1″ , or L 1′″ are composed of one or more linker components, selected from 6-maleimidocaproyl (“MC”), maleimidopropanoyl (“MP”), valine-citrulline (“val-cit” or “vc”), alanine-phenylalanine (“ala-phe” or “af”), p-aminobenzyloxycarbonyl (“PAB”), 4-thiopentanoate (“SPP”), 4-(N-maleimidomethyl)-cyclohexane-1 carboxylate (“MCC”), (4-acetyl)aminobenzoate (“SIAB”), 4-thio-butyrate (SPDB), 4-thio-2-hydroxysulfonyl-butyrate (2-Sulfo-SPDB), ethyleneoxy —CH 2 CH 2 O— as one or more repeating units (“EO” or “PEO”).
2. The conjugate compound according to claim 1 , wherein a pair of thiols of the cell-binding agent which are linked to the linker are the inter chain disulfide atoms of the cell-binding agent that are reduced by a reduction agent of dithiothreitol (DTT), dithioerythritol (DTE), dithiolbutylamine (DTBA), L-glutathione (GSH), tris (2-carboxyethyl) phosphine (TCEP), 2-mercaptoethylamine (P-MEA), or/and beta mercaptoethanol (β-ME, 2-ME).
3. The conjugate compound according to claim 1 , wherein Drug, Drug′, or Drug″ is a chromophore molecule.
4. The conjugate compound according to claim 1 , wherein one, two or all of the Drug, Drug′, or Drug″ are independently a poly(ethylene glycol) (PEGs), poly(propylene glycol), or a copolymer of ethylene oxide or propylene oxide.
5. The conjugate compound according to claim 1 , wherein one, two or all of the Drug, Drug′, or Drug″ are independently a cell-binding ligand or a cell receptor agonist, or a cell receptor binding molecule.
6. The conjugate compound according to claim 1 , wherein Drug, Drug′, or Drug″ is selected from the group consisting of tubulysins, calicheamicins, auristatins, maytansinoids, CC-1065 compounds, daunorubicin and doxorubicin compounds, taxanoids (taxanes), cryptophycins, epothilones, benzodiazepine dimers (selected from the group consisting of dimmers of pyrrolobenzodiazepine (PBD), tomaymycins, anthramycins, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidinobenzodiazepines), calicheamicins and the enediyne antibiotics, actinomycins, amanitins, azaserines, bleomycins, epirubicins, tamoxifen, idarubicin, dolastatins/auristatins (selected from the group consisting of monomethyl auristatin E, MMAE, MMAF, auristatin PYE, auristatin TP, Auristatins 2-AQ, 6-AQ, EB (AEB), and EFP (AEFP)), duocarmycins, geldanamycins, methotrexates, thiotepa, vindesines, vincristines, hemiasterlins, nazumamides, microginins, radiosumins, alterobactins, microsclerodermins, theonellamides, esperamicins, siRNA, miRNA, piRNA, nucleolytic enzymes, and/or pharmaceutically acceptable salts, or acids of any of the above molecules.
7. The conjugate compound according to claim 1 , wherein Cb is selected from the group consisting of an antibody, a full-length antibody (polyclonal antibody, monoclonal antibody, antibody dimer, antibody multimer, or multispecific antibody (selected from, bispecific or trispecific antibody)); a single chain antibody, an antibody fragment that binds to the target cell, a monoclonal antibody, a single chain monoclonal antibody, or a monoclonal antibody fragment that binds the target cell, a chimeric antibody, a chimeric antibody fragment that binds to the target cell, a domain antibody, a domain antibody fragment that binds to the target cell, a resurfaced antibody, a resurfaced single chain antibody, or a resurfaced antibody fragment that binds to the target cell, probody, a humanized antibody or a resurfaced antibody, a humanized single chain antibody, or a humanized antibody fragment that binds to the target cell, or anti-idiotypic (anti-Id) antibody.
8. The conjugate compound according to claim 1 , wherein Cb is a molecule or agent that is able to target against a tumor cell, a virus infected cell, a microorganism infected cell, a parasite infected cell, an autoimmune disease cell, an activated tumor cells, a myeloid cell, an activated T-cell, an affecting B cell, or a melanocyte, or cells expressing one or more of the following antigens or receptors: CD3, CD4, CD5, CD6, CD7, CD8, CD9, CD10, CD11a, CD11b, CD11c, CD12w, CD14, CD15, CD16, CDw17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42, CD43, CD44, CD45, CD46, CD47, CD48, CD49b, CD49c, CD51, CD52, CD53, CD54, CD55, CD56, CD58, CD59, CD61, CD62E, CD62L, CD62P, CD63, CD66, CD68, CD69, CD70, CD72, CD74, CD79, CD79a, CD79b, CD80, CD81, CD82, CD83, CD86, CD87, CD88, CD89, CD90, CD91, CD95, CD96, CD98, CD100, CD103, CD105, CD106, CD109, CD123, CD117, CD120, CD125, CD126, CD127, CD133, CD134, CD135, CD137, CD138, CD141, CD142, CD143, CD144, CD147, CD151, CD147, CD152, CD154, CD156, CD158, CD163, CD166, CD168, CD174, CD180, CD184, CDwl86, CD194, CD195, CD200, CD200a, CD200b, CD209, CD221, CD227, CD235a, CD240, CD262, CD271, CD274, CD276 (B7-H3), CD303, CD304, CD309, CD326, 4-1BB, 5AC, 5T4 (Trophoblast glycoprotein, TPBG, 5T4, Wnt-Activated Inhibitory Factor 1 or WAIF1), Adenocarcinoma antigen, AGS-5, AGS-22M6, Activin receptor-like kinase 1, AFP, AKAP-4, ALK, Alpha intergrin, Alpha v beta6, Amino-peptidase N, Amyloid beta, Androgen receptor, Angiopoietin 2, Angiopoietin 3, Annexin A1, Anthrax toxin protective antigen, Anti-transferrin receptor, AOC3 (VAP-1), B7-H3, Bacillus anthracis anthrax, BAFF (B-cell activating factor), BCMA, B-lymphoma cell, bcr-abl, Bombesin, BORIS, C5, C242 antigen, CA125 (carbohydrate antigen 125, MUC16), CA-IX (or CAIX, carbonic anhydrase 9), CALLA, CanAg, Canis lupus familiaris IL31, Carbonic anhydrase IX, Cardiac myosin, CCL11 (C—C motif chemokine 11), CCR4 (C—C chemokine receptor type 4, CD194), CCR5, CD3E (epsilon), CEA (Carcinoembryonic antigen), CEACAM3, CEACAM5 (carcino-embryonic antigen), CFD (Factor D), Ch4D5, Cholecystokinin 2 (CCK2R), CLDN18 (Claudin-18), Clumping factor A, cMet, CRIPTO, FCSF1R (Colony stimulating factor 1 receptor, CD115), CSF2 (colony stimulating factor 2, Granulocyte-macrophage colony-stimulating factor (GM-CSF)), CSP4, CTLA4 (cytotoxic T-lymphocyte-associated protein 4), CTAA16.88 tumor antigen, CXCR4 (CD184), C—X—C chemokine receptor type 4, cyclic ADP ribose hydrolase, Cyclin B1, CYP1B1, Cytomegalovirus, Cytomegalovirus glycoprotein B, Dabigatran, DLL3 (delta-like-ligand 3), DLL4 (delta-like-ligand 4), DPP4 (Dipeptidyl-peptidase 4), DR5 (Death receptor 5), E. coli shiga toxin type-1, E. coli shiga toxin type-2, ED-B, EGFL7 (EGF-like domain-containing protein 7), EGFR, EGFRII, EGFRvIII, Endoglin (CD105), Endothelin B receptor, Endotoxin, EpCAM (epithelial cell adhesion molecule), EphA2, Episialin, ERBB2 (Epidermal Growth Factor Receptor 2), ERBB3, ERG (TMPRSS2 ETS fusion gene), Escherichia coli , ETV6-AML, FAP (Fibroblast activation protein alpha), FCGR1, alpha-Fetoprotein, Fibrin II, beta chain, Fibronectin extra domain-B, FOLR (folate receptor), Folate receptor alpha, Folate hydrolase, Fos-related antigen 1F protein of respiratory syncytial virus, Frizzled receptor, Fucosyl GM1, GD2 ganglioside, G-28 (a cell surface antigen glyvolipid), GD3 idiotype, GloboH, Glypican 3, N-glycolylneuraminic acid, GM3, GMCSF receptor α-chain, Growth differentiation factor 8, GP100, GPNMB (Trans-membrane glycoprotein NMB), GUCY2C (Guanylate cyclase 2C, guanylyl cyclase C (GC-C), intestinal Guanylate cyclase, Guanylate cyclase-C receptor, Heat-stable enterotoxin receptor (hSTAR)), Heat shock proteins, Hemagglutinin, Hepatitis B surface antigen, Hepatitis B virus, HER1 (human epidermal growth factor receptor 1), HER2, HER2/neu, HER3 (ERBB-3), IgG4, HGF/SF (Hepatocyte growth factor/scatter factor), HHGFR, HIV-1, Histone complex, HLA-DR (human leukocyte antigen), HLA-DR10, HLA-DRB, HMWMAA, Human chorionic gonadotropin, HNGF, Human scatter factor receptor kinase, HPV E6/E7, Hsp90, hTERT, ICAM-1 (Intercellular Adhesion Molecule 1), Idiotype, IGF1R (IGF-1, insulin-like growth factor 1 receptor), IGHE, IFN-γ, Influenza hemagglutinin, IgE, IgE Fc region, IGHE, IL-1, IL-2 receptor (interleukin 2 receptor), IL-4, IL-5, IL-6, IL-6R (interleukin 6 receptor), IL-9, IL-10, IL-12, IL-13, IL-17, IL-17A, IL-20, IL-22, IL-23, IL31RA, ILGF2 (Insulin-like growth factor 2), Integrins (a4, α IIb β 3 , αvβ 3 , α 4 β 7 , α5β1, α6β4, α7β7, αllβ3, α5β5, αvβ5), Interferon gamma-induced protein, ITGA2, ITGB2, KIR2D, Kappa Ig, LCK, Le, Legumain, Lewis-Y antigen, LFA-1 (Lymphocyte function-associated antigen 1, CD11a), LHRH, LINGO-1, Lipoteichoic acid, LIV1A, LMP2, LTA, MAD-CT-1, MAD-CT-2, MAGE-1, MAGE-2, MAGE-3, MAGE A1, MAGE A3, MAGE 4, MART1, MCP-1, MIF (Macrophage migration inhibitory factor, or glycosylation-inhibiting factor (GIF)), MS4A1 (membrane-spanning 4-domains subfamily A member 1), MSLN (mesothelin), MUC1 (Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM)), MUC1-KLH, MUC16 (CA125), MCP1 (monocyte chemotactic protein 1), MelanA/MART1, ML-IAP, MPG, MS4A1 (membrane-spanning 4-domains subfamily A), MYCN, Myelin-associated glycoprotein, Myostatin, NA17, NARP-1, NCA-90 (granulocyte antigen), Nectin-4 (ASG-22ME), NGF, Neural apoptosis-regulated proteinase 1, NOGO-A, Notch receptor, Nucleolin, Neu oncogene product, NY—BR-1, NY-ESO-1, OX-40, OxLDL (Oxidized low-density lipoprotein), OY-TES1, P21, p53 nonmutant, P97, Page4, PAP, Paratope of anti-(N-glycolylneuraminic acid), PAX3, PAX5, PCSK9, PDCD1 (PD-1, Programmed cell death protein 1, CD279), PDGF-Rα (Alpha-type platelet-derived growth factor receptor), PDGFR-β, PDL-1, PLAC1, PLAP-like testicular alkaline phosphatase, Platelet-derived growth factor receptor beta, Phosphate-sodium co-transporter, PMEL 17, Polysialic acid, Proteinase3 (PR1), Prostatic carcinoma, PS (Phosphatidylserine), Prostatic carcinoma cells, Pseudomonas aeruginosa , PSMA, PSA, PSCA, Rabies virus glycoprotein, RHD (Rh polypeptide 1 (RhPI), CD240), Rhesus factor, RANKL, RhoC, Ras mutant, RGS5, ROBO4, Respiratory syncytial virus, RON, ROR1, Sarcoma translocation breakpoints, SART3, Sclerostin, SLAMF7 (SLAM family member 7), Selectin P, SDC1 (Syndecan 1), sLe(a), Somatomedin C, SIP (Sphingosine-1-phosphate), Somatostatin, Sperm protein 17, SSX2, STEAP1 (six-transmembrane epithelial antigen of the prostate 1), STEAP2, STn, TAG-72 (tumor associated glycoprotein 72), Survivin, T-cell receptor, T cell transmembrane protein, TEM1 (Tumor endothelial marker 1), TENB2, Tenascin C (TN-C), TGF-α, TGF-β (Transforming growth factor beta), TGF-β1, TGF-β2 (Transforming growth factor-beta 2), Tie (CD202b), Tie2, TIM-1 (CDX-014), Tn, TNF, TNF-α, TNFRSF8, TNFRSF10B (tumor necrosis factor receptor superfamily member 10B), TNFRSF-13B (tumor necrosis factor receptor superfamily member 13B), TPBG (trophoblast glycoprotein), TRAIL-R1 (Tumor necrosis apoprosis Inducing ligand Receptor 1), TRAILR2 (Death receptor 5 (DR5)), tumor-associated calcium signal transducer 2, tumor specific glycosylation of MUC1, TWEAK receptor, TYRP1 (glycoprotein 75), TRP-2, Tyrosinase, VCAM-1 (CD106), VEGF, VEGF-A, VEGF-2 (CD309), VEGFR-1, VEGFR2, or vimentin, WT1, XAGE 1, or cells expressing any insulin growth factor receptors, or any epidermal growth factor receptors.
9. The conjugate compound according to claim 8 , wherein the tumor cell is selected from the group consisting of lymphoma cells, myeloma cells, renal cells, breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cancer cells, small-cell lung cancer cells, non small-cell lung cancer cells, testicular cancer cells, malignant cells, and cells that grow and divide at an unregulated, quickened pace to cause cancers.
10. The linker compound according to claim 1 , wherein L 1 , L 1′ , and L 1″ are independently one or more, or repeating, or a combining of, components of following structures:
6-maleimidocaproyl (MC),
maleimido propanoyl (MP),
valine-citrulline (val-cit),
alanine-phenylalanine (ala-phe),
lysine-phenylalanine (lys-phe),
p-aminobenzyloxycarbonyl (PAB),
4-thio-pentanoate (SPP),
4-thio-butyrate (SPDB),
4-(N-maleimidomethyl)cyclo-hexane-1-carboxylate (MCC),
maleimidoethyl (ME),
4-thio-2-hydroxysulfonyl-butyrate (2-Sulfo-SPDB),
aryl-thiol (PySS),
(4-acetyl)aminobenzoate (SIAB),
oxylbenzylthio,
aminobenzylthio,
dioxylbenzylthio,
diaminobenzylthio,
amino-oxylbenzylthio,
alkoxy amino (AOA),
ethyleneoxy (EO),
4-methyl-4-dithio-pentanoic (MPDP),
triazole,
dithio,
alkylsulfonyl,
alkylsulfonamide,
sulfon-bisamide,
Phosphondiamide,
alkylphosphonamide,
phosphinic acid,
N-methylphosphonamidic acid,
N,N′-dimethylphosphon-amidic acid,
N,N′-dimethylphosphondiamide,
hydrazine,
acetimidamide;
oxime,
acetylacetohydrazide,
aminoethyl-amine,
aminoethyl-aminoethyl-amine, and L- or D-, natural or unnatural peptides containing 1-20 amino acids, wherein “ ” is the site of linkage (or connection).
11. The linker compound according to claim 1 , wherein L 1 , L 1 ′, and L 1 ″ is independently selected from the group consisting of one or more, or repeating, or a combination of, components of following structures: —(CR 5 R 6 ) m (Aa)r(CR 7 R 8 ) n (OCH 2 CH 2 ) t —, —(CR 5 R 6 ) m (CR 7 R 8 ) n (Aa) r (OCH 2 CH 2 ) t —, -(Aa) r -(CR 5 R 6 ) m (CR 7 R 8 ) n (OCH 2 CH 2 ) t —, —(CR 5 R 6 ) m (CR 7 R 8 ) n (OCH 2 CH 2 ) r (Aa) t -, —(CR 5 R) m —(CR 7 ═CR 8 )(CR 9 R 10 ) n (Aa) t (OCH 2 CH 2 ) r —, —(CR 5 R 6 ) m (NR 11 CO)(Aa) t (CR 9 R 10 ) n —(OCH 2 CH 2 ) r —, —(CR 5 R 6 ) m (Aa) t (NR 11 CO)(CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —(CR 5 R 6 ) m (OCO)(Aa) t (CR 9 R 10 ) n —(OCH 2 CH 2 ) r —, —(CR 5 R 6 ) m (OCNR 7 )(Aa) t (CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —(CR 5 R 6 ) m (CO)(Aa) t -(CR 9 R 10 ) n —(OCH 2 CH 2 ) r —, —(CR 5 R 6 ) m (NR 11 CO)(Aa) t (CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —(CR 5 R 6 ) m —(OCO)(Aa) t (CR 9 R 10 ) n —(OCH 2 CH 2 ) r —, —(CR 5 R 6 ) m (OCNR 7 )(Aa) t (CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —(CR 5 R 6 ) m (CO)(Aa) t (CR 9 R 10 ) n —(OC 12 CH 2 ) r —, —(CR 5 R 6 ) m -phenyl-CO(Aa) t (CR 7 R 8 ) n —, —(CR 5 R 6 ) m -furyl-CO(Aa) t (CR 7 R 8 ) n —, —(CR 5 R 6 ) m -oxazolyl-CO(Aa) t (CR 7 R 8 ) n —, —(CR 5 R 6 ) m -thiazolyl-CO(Aa) t (CCR 7 R 8 ) n —, —(CR 5 R 6 ) t -thienyl-CO(CR 7 R 8 ) n —, —(CR 5 R 6 ) t -imidazolyl-CO—(CR 7 R 8 ) n —, —(CRR) t -morpholino-CO(Aa) t -(CR 7 R 8 ) n —, —(CR 5 R 6 ) t piperazino-CO(Aa) t -(CR 7 R 8 ) n —, —(CR 5 R 6 ) t —N-methylpiperazin-CO(Aa) t -(CR 7 R 8 ) n —, —(CR 5 R) m -(Aa) t phenyl-, —(CR 5 R 6 ) m -(Aa) t furyl-, —(CR 5 R 6 ) m -oxazolyl(Aa) t -, —(CR 5 R 6 ) m -thiazolyl(Aa) t -, —(CR 5 R 6 ) m -thienyl-(Aa) t -, —(CR 5 R 6 ) m -imidazolyl(Aa) t -, —(CR 5 R 6 ) m -morpholino-(Aa) t -, —(CR 5 R 6 ) m -piperazino-(Aa) t -, —(CR 5 R 6 ) m —N-methylpiperazino-(Aa) t -, —K(CR 5 R 6 ) m (Aa) t (CR 7 R 8 ) n (OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m (CR 7 R 8 ) n (Aa) r (OCH 2 CH 2 ) t —, —K(Aa) r -(CR 5 R 6 ) m (CR 7 R 8 ) n (OCH 2 CH 2 ) t —, —K(CR 5 R 6 ) m (CR 7 R 8 ) n (OCH 2 CH 2 ) r (Aa) t -, —K(CR 5 R 6 ) m —(CR 7 ═CR 8 )(CR 9 R 10 ) n (Aa) t (OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m (NR 11 CO)(Aa) t (CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m (Aa) t (NR 11 CO)(CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m (OCO)(Aa) t (CR 9 R 10 ) n —(OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m (OCNR 7 )(Aa) t (CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m (CO)(Aa) t -(CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m (NR 11 CO)(Aa) t (CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m —(OCO)(Aa) t (CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m (OCNR 7 )(Aa) t (CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —K—(CR 5 R 6 ) m (CO)(Aa) t (CR 9 R 10 ) n (OCH 2 CH 2 ) r —, —K(CR 5 R 6 ) m -phenyl-CO(Aa) t (CR 7 R 8 ) n —, —K—(CR 5 R 6 ) m -furyl-CO(Aa) t -(CR 7 R 8 ) n —, —K(CR 5 R 6 ) m -oxazolyl-CO(Aa) t (CR 7 R 8 ) n —, —K(CR 5 R 6 ) m -thiazolyl-CO(Aa) t -(CR 7 R 8 ) n —, —K(CR 5 R 6 ) t -thienyl-CO(CR 7 R 8 ) n —, —K(CR 5 R 6 ) t imidazolyl-CO—(CR 7 R 8 ) n —, —K(CR 5 R 6 ) t morpholino-CO(Aa) t (CR 7 R 8 ) n —, —K(CR 5 R 6 ) t piperazino-CO(Aa) t -(CR 7 R 8 ) n —, —K(CR 5 R 6 )—N- methylpiperazinCO(Aa) t (CR 7 R 8 ) n —, —K(CR 5 R) m (Aa) t phenyl, —K—(CR 5 R 6 ) m -(Aa) t furyl-, —K(CR 5 R 6 ) m -oxazolyl(Aa) t -, —K(CR 5 R 6 ) m -thiazolyl(Aa) t -, —K(CR 5 R 6 ) m -thienyl-(Aa) t -, —K(CR 5 R 6 ) m -imidazolyl(Aa) t -, —K(CR 5 R 6 ) m -morpholino(Aa) t -, —K(CR 5 R 6 ) m -piperazino-(Aa) t G, —K(CR 5 R 6 ) m N-methylpiperazino(Aa) t -;
wherein m, Aa, m, n, R 3 , R 4 , and R 5 are described in claim 1 ; t and r are 0-100 independently; R 6 , R 7 , and R 8 are independently H; halide; C 1 ˜C 8 of alkyl, aryl, alkenyl, alkynyl, ether, ester, amine or amide, which optionally substituted by one or more halide, CN, NR 1 R 2 , CF 3 , OR 1 , Aryl, heterocycle, S(O)R 1 , SO 2 R 1 , —CO 2 H, —SO 3 H, —OR 1 , —CO 2 R 1 , —CONR 1 , —PO 2 R 1 R 2 , —PO 3 H or P(O)R 1 R 2 R 3 ; K is NR 1 , —SS—, —C(═O)—, —C(═O)NH—, —C(═O)O—, —C═NH—O—, —C═N—NH—, —C(═O)NH—NH—, O, S, Se, B, heterocyclic or heteroaromatic ring having C 3 -C 8 , or peptides containing 1-20 amino acids.
12. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is a Tubulysin compound, the conjugate compound is selected from the group consisting of structures of T09, T10, and T12 as following:
wherein “ ”, n, m 1 , m 2 , X 1 , X 2 , L 1 , L 2 , L 3 , R 1 , R 2 , R 3 , R 4 , and R 5 are defined the same as in claim 1 ; mAb is an antibody, or a cell-binding molecule; Z 3 is H, OP(O)(OM 1 )(OM 2 ), OOCCH 3 , OCH 2 OP(O)(OM 1 )(OM 2 ), OSO 3 M 1 , R 1 , or O-glycoside (including glucoside, galactoside, mannoside, glucuronoside/glucuronide, alloside, fructoside), NH-glycoside, S-glycoside or CH 2 -glycoside; two Rs: R 1 and R 2 , R 2 and R 3 , R 1 and R 3 or R 3 and R 4 can form 3-8 member cyclic ring of alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; X 3 is H, CH 3 , or X 1 ′R 1 ′, wherein X 1 ′ is NH, N(CH 3 ), NHNH, O, or S, and R 1 ′ is H or C 1 -C 8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, or acyloxylamines; R 1 ′ and R 3 ′ are independently H or C 1 -C 6 linear or branched alkyl; p is 0-2000; M 1 and M 2 are independently H, Na, K, Ca, Mg, NH 4 , or NR 1 R 2 R 3 ; Drug 1 is another tubulysin compound or a cytotoxic agent, or R 1 ′ can be a cytotoxic agent or drug.
13. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is a Taxane compound, the conjugate compound is as following:
wherein mAb is an antibody or a cell-binding molecule; “ ”, n, and m 1 are defined the same in claim 1 ; X 1 and X 2 are independently defined as X 1 in claim 1 ; L 1 and L 2 are independently defined as L 1 in claim 1 ; R 1 ′ and R 3 ′ are independently H or C 1 -C 6 linear or branched alkyl; p is 0-2000, or R 1 ′ can be a cytotoxic agent, or a drug.
14. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is a CC-1065 compound and/or duocarmycin compound, the conjugate compound is as following:
wherein mAb is an antibody or a cell-binding molecule; X 3 is O, NH, NHC(O), OC(O), —C(O)O, R 1 , or absent; “ ”, n, and m 1 are defined the same in claim 1 ; X 1 and X 2 are independently defined as X 1 in claim 1 ; L 1 and L 2 are independently defined as L 1 in claim 1 , R 1 ′ and R 3 ′ are independently H or C 1 -C 6 linear or branched alkyl; p is 0-2000, or R 1 ′ can be a cytotoxic agent, or a drug.
15. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is a Daunorubicin or Doxorubicin compound, the conjugate compound is selected from the group consisting of structures of Da03 and Da04 as following:
wherein mAb is an antibody or a cell-binding molecule; X 3 is O, NH, NHC(O), NHC(O)NH, C(O), R 1 , OC(O), or absent; “ ”, n, and m 1 are defined the same in claim 1 ; X 1 and X 2 are independently defined as X 1 in claim 1 ; L 1 and L 2 are independently defined as L 1 in claim 1 ; R 1 ′ and R 3 ′ are independently H or C 1 -C 6 linear or branched alkyl; p is 0-2000, or R 1 ′ can be a cytotoxic agent, or a drug.
16. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is an Auristatin or dolastatin compound, the conjugate compound is selected from the group consisting of structures of Au05 and Au08 as following:
wherein “ ”, n, m 1 , R 1 , R 2 , R 3 , R 4 and R 5 are the same defined in claim 1 ; mAb is an antibody, or a cell-binding molecule; L 1 , and L 2 , are independently defined as L 1 in claim 1 ; Z 3 ′ is H, OP(O)(OM 1 )(OM 2 ), OOCCH 3 , OCH 2 OP(O)(OM 1 )(OM 2 ), OSOM 1 , R 1 , or O-glycoside (including glucoside, galactoside, mannoside, glucuronoside/glucuronide, alloside, fructoside), NH-glycoside, S-glycoside or CH 2 -glycoside; two Rs: R 1 R 2 , R 2 R 3 , R 1 R 3 or R 3 R 4 can form 3˜8 member cyclic ring of alkyl, aryl, heteroaryl, heteroalkyl, or alkylcycloalkyl group; X 3 is H, CH 3 , or X 1 ′R 1 ′, wherein X 1 ′ is NH, N(CH 3 ), NHNH, O, or S, and R 1 ′ is H or C 1 -C 8 linear or branched alkyl, aryl, heteroaryl, heteroalkyl, alkylcycloalkyl, or acyloxylamines; R 3 ′ is H or C 1 -C 6 linear or branched alkyl; p is 0-2000; M 1 and M 2 are independently H, Na, K, Ca, Mg, NH 4 , NR 1 R 2 R 3 ; or R 1 ′, Drug 1 and Drug 2 can be a cytotoxic agent.
17. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is a dimer of benzodiazepine compound, the conjugate compound is selected from the group consisting of structures of PB05, PB09, and PB10:
wherein “ ”, n, m 1 , R 1 , R 2 , and R 3 are the same defined in claim 1 ; L 1 and L 2 are independently defined as L 1 in claim 1 ; mAb is an antibody, or a cell-binding molecule; X 3 is CH 2 , O, NH, NHC(O), NHC(O)NH, C(O), OC(O), OC(O)(NR 3 ), R 1 , NHR 1 , NR 1 C(O)R 1 or absent; X 4 is CH 2 , C(O), C(O)NH, C(O)N(R 1 ), R 1 , NHR 1 , NR 1 C(O)R 1 or C(O)O; M 1 is H Na K, Ca, Mg, NH 4 , NR 1 R 2 R 3 ; R 1 ′ and R 3 ′ are independently H or C 1 -C 6 linear or branched alkyl; p is 0-2000, or R 1 ′ can be a cytotoxic agent.
18. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is an amanitin compound, the conjugate compound is structure of Am02 below:
wherein “ ”, n, m 1 , and R 1 are the same defined in claim 1 ; L 1 and L 2 are independently defined as L 1 in claim 1 ; mAb is an antibody, or a cell-binding molecule; R 7 , R 8 , R 9 , R 10 and R 11 are independently H, OH, OR 1 , NH 2 , NHR 1 , C 1 -C 6 alkyl, or absent; Y 1 is O, O 2 , S, NH, or absent; R 1 ′ and R 3 ′ are independently H or C 1 -C 6 linear or branched alkyl; p is 0-2000, or R 1 ′ can be a cytotoxic agent.
19. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is a polyalkylene glycol compound, the conjugate compound is of structure of Pg05:
wherein “ ”, n, m 1 , m 2 , L 1 , R 1 , and R 3 are the same defined in claim 1 ; X 1 and X 2 are independently defined as X 1 in claim 1 ; mAb is an antibody, or a cell-binding molecule; p is 0-2000; Drug 1 is a cytotoxic agent.
20. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is a cell-binding ligand or cell receptor agonist compound, the conjugate compound is selected from the group consisting of following structures:
wherein “ ”, n, m 1 , m 2 , X 1 , X 2 , R 1 , R 2 , R 3 , and R 4 are the same defined in claim 1 ; mAb is an antibody, or a cell-binding molecule; L 1 , L 2 , L 3 , L 4 , and L 5 are independently defined as L 1 in claim 1 ; X 3 is CH 2 , O, NH, NHC(O), NHC(O)NH, C(O), OC(O), OC(O)(NR 3 ), R 1 , NHR 1 , NR 1 , C(O)R 1 or absent; X 4 is H, CH 2 , OH, O, C(O), C(O)NH, C(O)N(R 1 ), R 1 , NHR 1 , NR 1 , C(O)R 1 or C(O)O; M 1 and M 2 are independently H, Na, K, Ca, Mg, NH 4 , NR 1 R 2 R 3 ; R 6 =5′-deoxyadenosyl, Me, OH, or CN; R 1 ′ and R 3 ′ are independently H or C 1 -C 6 linear or branched alkyl; p is 0-2000, or R 1 ′ can be a cytotoxic agent, or R 1 can be absent and R 2 can be H.
21. The conjugate compound of claim 1 , wherein Drug, Drug′, or Drug″ is a DNA, RNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA), or PIWI interacting RNAs (piRNA), the conjugate compound is structure of SI-2 below:
wherein mAb is an antibody or a cell-binding molecule “ ”, n, m 1 , m 2 , m 3 , m 4 , X 1 , X 2 , X 3 , X 4 , X 5 , and R 1 are defined the same in claim 1 ; R 1 ′ and R 3 ′ are independently H or C 1 -C 6 linear or branched alkyl; p is 0-2000; is single or double strands of DNA, RNA, mRNA; Y is O, S, NH, CH 2 , N—R 1 ; L 1 , L 2 , L 1 ′ and L 2 ′ are independently defined as L 1 in claim 1 ; or R 1 ′ can be a cytotoxic agent, or a drug.
22. The conjugate according to claim 1 , which is selected from the group consisting of following structures, Z02, Z03, Z04, Z05, Z06, Z07, Z08, Z09, Z10, Z12, Z13, Z14, Z16, Z17 and Z18:
wherein “ ”, n, m 1 , m 2 , R 1 , R 2 , R 3 , and R 4 are the same defined in claim 1 ; X 1 and X 2 are independently defined as X 1 in claim 1 ; L 1 and L 2 are independently defined as L 1 in claim 1 ; mAb is an antibody, or a cell-binding molecule; X 3 and X′ 3 are independently CH 2 , O, NH, NHC(O), NHC(O)NH, C(O), OC(O), OC(O)(NR 3 ), R 1 , NHR 1 , NR 1 C(O)R 1 or absent; X 4 and X′ 4 are independently H, CH 2 , OH, O, C(O), C(O)NH, C(O)N(R 1 ), R 1 , NHR 1 , NR 1 , C(O)R 1 or C(O)O; M 1 and M 2 are independently H, Na, K, Ca, Mg, NH 4 , NR 1 R 2 R 3 ; or R 1 and/or R 2 can be absent independently.
23. The conjugate according to claim 1 , wherein the cell-binding agent is an IgG antibody, or monoclonal antibody, the conjugate containing one, or two, or more the same or differently cytotoxic agents conjugated specifically to a pair of thiols through reduction of a disulfide bond of the cell-binding agent between a light chain and heavy chain, an upper disulfide bond between two heavy chains and a lower disulfide bond between two heavy chains, as shown in following structures, ST2, ST4, ST6, ST8, ST10, ST12, or ST14:
wherein X 1 , X 1 ′, X 2 , X 2 ′, X 3 , X 3 ′, X 4 , X 4 ′, T, L 1 , L 1 ′, L 2 , L 2 ′, L 3 , L 3 ′, L 4 , L 4 ′, and “ ” are defined the same in claim 1 ; “ ” is the site to link a function molecule or cytotoxic agent, or X 1 , X 1 ′, X 2 , X 2 ′, X 3 , X 3 ′, X 4 , or X 4 ′, can be independently absent.
24. The conjugate according to claim 23 , wherein the cytotoxic agent is selected from the group consisting of tubulysins, maytansinoids, taxanoids (taxanes), CC-1065 compounds, daunorubicin and doxorubicin compounds, benzodiazepine dimers (selected from dimers of pyrrolobenzodiazepine (PBD), tomaymycin, anthramycin, indolinobenzodiazepines, imidazobenzothiadiazepines, or oxazolidinobenzodiazepines), calicheamicins and the enediyne antibiotics, actinomycin, amanitins (amatoxins), azaserines, bleomycins, epirubicin, tamoxifen, idarubicin, dolastatins, auristatins (selected from monomethyl auristatin E, MMAE, MMAF, auristatin PYE, auristatin TP, Auristatins 2-AQ, 6-AQ, EB (AEB), and EFP (AEFP)), duocarmycins, thiotepa, vincristines, hemiasterlins, nazumamides, microginins, radiosumins, alterobactins, microsclerodermins, theonellamides, esperamicins, and PNU-159682.
25. The conjugate compound according to claim 1 having one of following formulae:
wherein R′ is C 1 -C 4 alkyl; “ ”, m 1 , m 2 , p, drug, Z 3 , drug 1 , drug 2 , drug 3 , drug 4 , drug 5 , drug 6 , drug 7 , drug 8 , drug 1′ , m, and n are defined the same as in claim 2 ; L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , and L 8 are defined independently the same as L 1 in claim 1 .
26. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate compound of claim 1 , and a pharmaceutically acceptable salt, carrier, diluent, or excipient therefore, or a combination thereof.
27. The conjugate compound of claim 1 , having in vitro, in vivo or ex vivo cell killing activity.
28. The compound of claim 1 , wherein R 1 , R 1 ′, R 1 ″, L 1 , L 1 ′, and L 1 ″ are independently cleavable by a protease.
29. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate compound of claim 1 , and a synergistically effective amount of a chemotherapeutic agent, radiation therapy agent, immunotherapy agent, autoimmune disorder agent, or anti-infectious agent.
30. The pharmaceutical composition according to claim 29 comprising one or several of following drugs: Abatacept, Abiraterone acetate, Acetaminophen/hydrocodone, aducanumab, Adalimumab, ADXS31-142, ADXS-HER2, afatinib dimaleate, alemtuzumab, Alitretinoin, ado-trastuzumab emtansine, Amphetamine mixed salts, anastrozole, Aripiprazole, Atazanavir, Atezolizumab, Atorvastatin, axitinib, Avelumab, belinostat, Bevacizumab, Cabazitaxel, Cabozantinib, bexarotene, blinatumomab, Bortezomib, bosutinib, brentuximab vedotin, Budesonide, Budesonide/formoterol, Buprenorphine, Capecitabine, carfilzomib, Celecoxib, ceritinib, Cetuximab, Ciclosporin, Cinacalcet, crizotinib, Cosentyx, CTL019, Dabigatran, dabrafenib, Daratumumab, Darbepoetin alfa, Darunavir, imatinib mesylate, dasatinib, denileukin diftitox, Denosumab, Depakote, Dexlansoprazole, Dexmethylphenidate, Dexamethasone, Dignitana DigniCap Cooling System, Dinutuximab, Doxycycline, Duloxetine, Duvelisib, elotuzumab, Emtricitabine/Rilpivirine/Tenofovir disoproxil fumarate, Emtricitbine/tenofovir/efavirenz, Enoxaparin, Enzalutamide, Epoetin alfa, erlotinib, Esomeprazole, Eszopiclone, Etanercept, Everolimus, exemestane, everolimus, Ezetimibe, Ezetimibe/simvastatin, Fenofibrate, Filgrastim, fingolimod, Fluticasone propionate, Fluticasone/salmeterol, fulvestrant, gazyva, gefitinib, Glatiramer, Goserelin acetate, Icotinib, Imatinib, Ibritumomab tiuxetan, ibrutinib, idelalisib, Infliximab, iniparib, Insulin aspart, Insulin detemir, Insulin glargine, Insulin lispro, Interferon beta 1a, Interferon beta 1b, lapatinib, Ipilimumab, Ipratropium bromide/salbutamol, Ixazomi, Kanuma, Lanreotide acetate, lenalidomide, lenaliomide, lenvatinib mesylate, letrozole, Levothyroxine, Levothyroxine, Lidocaine, Linezolid, Liraglutide, Lisdexamfetamine, LN-144, MEDI4736, Memantine, Methylphenidate, Metoprolol, Mekinist, Modafinil, Mometasone, Nilotinib, niraparib, Nivolumab, ofatumumab, obinutuzumab, Olaparib, Olmesartan, Olmesartan/hydrochlorothiazide, Omalizumab, Omega-3 fatty acid ethyl esters, Oseltamivir, Oxycodone, palbociclib, Palivizumab, panitumumab, panobinostat, pazopanib, pembrolizumab, Pemetrexed, pertuzumab, Pneumococcal conjugate vaccine, pomalidomide, Pregabalin, ProscaVax, Propranolol, Quetiapine, Rabeprazole, radium 223 chloride, Raloxifene, Raltegravir, ramucirumab, Ranibizumab, regorafenib, Rituximab, Rivaroxaban, romidepsin, Rosuvastatin, ruxolitinib phosphate, Salbutamol, Sevelamer, Sildenafil, siltuximab, Sitagliptin, Sitagliptin/metformin, Solifenacin, solanezumab, Sorafenib, Sunitinib, Tadalafil, tamoxifen, Tafinlar, talazoparib, Telaprevir, temsirolimus, Tenofovir/emtricitabine, Testosterone gel, Thalidomide, Tiotropium bromide, toremifene, trametinib, Trastuzumab, Tretinoin, Ustekinumab, Valsartan, veliparib, vandetanib, vemurafenib, venetoclax, vorinostat, ziv-aflibercept, Zostavax, pharmaceutically acceptable salts, carriers, diluents, or excipients thereof, or a combination thereof.
31. The conjugate compound of claim 1 , wherein
L 1 , L 1′ or L 1″ comprises an amide bond.
32. The conjugate compound of claim 1 , wherein
L 1 , L 1′ or L 1″ comprises one or more of an amide bond, C 1 -C 8 alkyl or (OCH 2 CH 2 ) r .
33. The conjugate compound of claim 1 , wherein
L 1 , L 1′ or L 1″ is CH 2 CON or CH 2 CH 2 CON.
34. The conjugate compound of claim 1 , wherein
R 1 , R 1′ and R 1″ are independently C 1 -C 8 alkyl; alkylcarbonyl; C 2 -C 8 ester, ether, or amide; or
polyethyleneoxy unit of formula (OCH 2 CH 2 ) p or (OCH 2 CH(CH 3 )) p , wherein p is an integer from 0 to about 1000, or a combination thereof.